Group 1 - Biohaven Ltd. announced the pricing of its public offering of 5,263,158 common shares at $47.50 per share, with expected gross proceeds of approximately $250 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 789,473 common shares at the public offering price [1] - The offering is expected to close on October 2, 2024, subject to customary closing conditions [1] Group 2 - J.P. Morgan, Morgan Stanley, Jefferies, and TD Cowen are acting as the joint lead book-running managers for the offering [2] - The shares will be issued under an effective shelf registration statement on Form S-3 [4]

NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $250 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a ...

Shares of Biohaven Ltd. (BHVN) were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease. Currently, there are no FDA-approved therapy for the given indication. The study showed the efficacy of troriluzole on the mean change from baseline in the modified functional Scale for the Assessment and Rati ...

Biohaven Today BHVN Biohaven $45.03 -0.91 (-1.98%) 52-Week Range $16.48 ▼ $62.21 Price Target $59.00 Add to Watchlist Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA). This rare and debilitating neurodegenerative disease currently lacks FDA-approved treatments. The news sent Biohaven shares soaring as high as 20% on Monday, marking a si ...

Key Takeaways Biohaven said its experimental treatment for a rare neurological condition showed "a robust and clinically meaningful" slowing of the disease. The study of the drug troriluzole found a 50% to 70% slower rate of decline over three years for patients with spinocerebellar ataxia (SCA). The news sent Biohaven shares soaring 15% and moving into positive territory for the year. Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental ...

Core Insights - Biohaven Ltd. announced positive topline results from pivotal Study BHV4157-206-RWE, demonstrating the efficacy of troriluzole in treating Spinocerebellar Ataxia (SCA) over three years [1][3] - The study achieved its primary endpoint, showing statistically significant improvements in the f-SARA scale at years 1 and 2, indicating a robust treatment effect [1][3] - SCA is a rare neurodegenerative disease affecting approximately 15,000 individuals in the U.S. and 24,000 in Europe and the U.K. [1] Treatment Efficacy - Data from multiple analyses indicate a clinically meaningful slowing of disease progression in SCA patients treated with troriluzole, translating to a 50-70% slower rate of decline compared to untreated patients [2] - The treatment represents a delay in disease progression of 1.5-2.2 years over the three-year study period [2] - The odds ratio for disease progression in untreated patients compared to those treated with troriluzole was 4.1, highlighting the treatment's effectiveness [3] Regulatory and Commercial Plans - Biohaven plans to submit a New Drug Application (NDA) to the FDA in Q4 2024, aiming for commercialization of SCA treatment in the U.S. by 2025, contingent on approval [3][4] - The troriluzole development program has generated the largest clinical trial dataset in SCA, with some patients followed for over five years [4] Market Reaction - Following the announcement, Biohaven's stock rose by 12%, reaching $45.20 in premarket trading [4]

Core Insights - Biohaven Ltd. will host a conference call on September 23, 2024, to discuss topline data from Study BHV4157-206-RWE, which assesses the effectiveness of troriluzole in Spinocerebellar Ataxia [1][2] Group 1: About Troriluzole - Troriluzole is a new chemical entity and third-generation prodrug that modulates glutamate, the most abundant excitatory neurotransmitter in the human body [3] - The primary mode of action of troriluzole is to reduce synaptic levels of glutamate by increasing its uptake from the synapse [3] - Troriluzole has potential applications in various diseases associated with excessive glutamate [3] Group 2: About Biohaven - Biohaven is a biopharmaceutical company focused on discovering, developing, and commercializing treatments in key therapeutic areas such as immunology, neuroscience, and oncology [4] - The company is advancing an innovative portfolio of therapeutics, leveraging proven drug development experience and proprietary drug development platforms [4] - Biohaven's clinical and preclinical programs include treatments for epilepsy, mood disorders, immunological diseases, migraine, neuropathic pain, neuroinflammatory disorders, and neuromuscular diseases [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Biohaven Ltd. WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41477 (Exact name of registrant as specified in its charter) British Virgin Islands Not applicable (State or other jurisdiction of incorporation or or ...

Exhibit 99.1 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments • Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 • Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing multiple new targets and reported positive interim data from its lead investigational drug in an ongoing Phase 1 study of BHV-1300: ◦ The Company reported dose-dependent and rapid IgG reductions in its ongo ...

The clinical progress, regulatory updates and pipeline developments at Biohaven's R&D Day include: Molecular Degrader of Extracellular Proteins (MoDE) Platform: Harnessing a New Modality with Transformational Potential for the Treatment of Immunological and Inflammatory Disorders The Company unveiled new positive data from its ongoing Phase 1 single ascending dose (SAD) study with BHV-1300, a first-in-human IgG degrader that uses an ASGPR-bispecific from its MoDE platform. Emerging results in healthy subjec ...